To give or not to give? Lessons from the arginine paradox by F. S. Dioguardi
90
 © 2011 S. Karger AG, Basel
1661–6499/11/0042–0090$38.00/0 
 Review 
 J Nutrigenet Nutrigenomics 2011;4:90–98 
 DOI: 10.1159/000327777 
 To Give or Not to Give? Lessons 
from the Arginine Paradox 
 Francesco Saverio Dioguardi 
 Department of Internal Medicine, University of Milan,  Milan , Italy 
 Key Words 
 Amino acids   Arginine   Citric acid cycle   Glutamine   Malnutrition   Nitric oxide   
Nitric oxide synthases 
 Abstract 
 Arginine is one of the 20 amino acids (AA) found in proteins and synthesized by human cells. 
However, arginine is also the substrate for a series of reactions leading to the synthesis of other 
AA and is an obligatory substrate for two enzymes with diverging actions, arginases and nitric 
oxide synthases (NOS), giving origin to urea and NO, respectively. NO is a very potent vasodila-
tor when produced by endothelial NOS (eNOS). The ‘arginine paradox’ is the fact that, despite 
intracellular physiological concentration of arginine being several hundred micromoles per li-
ter, far exceeding the   5   M K M of eNOS, the acute provision of exogenous arginine still in-
creases NO production. Clinically, an additional paradox is that the largest controlled study on 
chronic oral arginine supplementation in patients after myocardial infarction had to be inter-
rupted for excess mortality in treated patients. Expression and activity of arginases, which pro-
duce urea and divert arginine from NOS, are positively related to exogenous arginine supple-
mentation. Therefore, the more arginine is introduced, the more it is destroyed, eventually 
leading to impaired NO production. In this review, conditions influencing the low arginine con-
centrations found in plasma will be reviewed, revising the paradigm that simple replenishment 
of what is lacking will always produce beneficial consequences.  Copyright © 2011 S. Karger AG, Basel 
 Arginine, Nitric Oxide and Related Paradoxes 
 Arginine is one of the 20 amino acids (AA) necessary for protein synthesis and coded by 
DNA. Plasma arginine concentrations are therefore maintained mostly by protein catabo-
lism ( ; 85%)  [1] or by synthesis from other AA. Of the total synthesis,  de novo synthesis ac-
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counts for  ! 15%, while 60% of arginine is derived from citrulline  [2] . Arginine metabolism 
may give rise to several other AA and molecules indispensable for life ( fig. 1 ). Exogenous ar-
ginine is largely destroyed ( ; 40%) during absorption by the gut itself. Much attention was 
given to arginine availability due to the discovery in the 1980s that ‘endothelium-dependent 
relaxing factor’ is a gas, nitric oxide (NO), produced from arginine by endothelial NO syn-
thases (eNOS)  [3] in a reaction that gives also rise to citrulline. In endothelial cells, eNOS 
and the two sequential enzymes argininosuccinate lyase (ASL) and argininosuccinate syn-
thase (ASsynth), necessary for recycling citrulline to arginine, are co-localized in the caveo-
lae  [4] , a fraction of cell membranes that provides an efficient environment for maintaining 
arginine available to eNOS. The cytoplasm of endothelial cells has a concentration of argi-
nine largely saturating eNOS, and yet the acute introduction of exogenous arginine elicits an 
increase in NO production, a puzzling finding known as ‘the arginine paradox’  [5] . Another 
puzzling finding is the peculiar regulation of arginine transport and its effects on NO. The 
transport of arginine into cells is mediated by the cationic AA transporter 1 (CAT1). Over-
expression of CAT1 enhances arginine uptake sixfold, and NO production twofold. The 
presence of AA competing with arginine decreases arginine uptake, but not NO production 
 [4] . Moreover, citrulline succeeds in stimulating NO production even in a medium contain-
ing saturating levels of arginine, and extracellular citrulline does not influence intracellular 
arginine levels. Therefore, NO production depends mostly on the efficient recycling of argi-
nine-derived citrulline back to arginine, and not so much on exogenous arginine supply. 
Thus, the presence of a ‘micro-environment’, where arginine metabolism and recycling are 
independently regulated and only partially in balance with plasma arginine concentrations, 
is the most consistent explanation for the endothelial arginine paradox  [6] .
 An even more puzzling paradox is that long-term arginine supplementation is ineffec-
tive in improving eNOS activity  [7, 8] . Even worse, exogenous arginine increased mortality 
when arginine was given to promote vasodilation in patients after a myocardial infarction 
 [9] . We will now analyze these findings in more detail.
 Endothelial Vasomotion and the Exogenous Arginine Paradox 
 To understand the clinical paradox of arginine, i.e. the fact that the much needed argi-
nine is ineffective or actually detrimental when supplemented chronically, we have to focus 
on another pathway of the complex arginine metabolism ( fig. 1 ), which is controlled by the 
ubiquitous enzymes arginases (in two types, 1 and 2), which compete with NOS for arginine 
as a substrate. The effect of both arginases is to catalyze the cleavage of urea from arginine, 
thus forming ornithine. Urea controls osmolarity and water content of plasma and cells. The 
other product of the reaction, ornithine, may be recycled to citrulline and also synthesized 
de novo by the liver from glutamine, and then transformed by the gut into citrulline. The 
kidneys provide the further recycling of citrulline to arginine, finally released into the plas-
ma  [8] . Arginase 1 (ARG 1) is a cytosolic enzyme, mostly expressed in the liver and red blood 
cells. Deletion of the ARG 1 gene, as occasionally found in humans, is incompatible with 
prolonged life, and the accompanying hyperargininemia is associated with a several-fold in-
crease in the activity of the mitochondrial arginase (ARG 2), which accounts for the persis-
tent ureagenesis in those patients  [10] . ARG 2 is widely expressed, mostly in the kidneys, gut 
and brain. ARG 2 overexpression plays a critical role in the pathophysiology of cholesterol-
mediated endothelial dysfunction  [11] . Arginases and NOS compete for arginine, and – un-
der any conditions – arginase activity exceeds NOS activity at all NOS/arginase molar ratios 
 [12] . Moreover, although the K M of arginases is 100-fold higher than that of NOS, the en-
zymes compete for arginine because the maximal catalytic rate of arginases is more than 
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1,000 times higher than that of NOS  [2, 13] . Therefore, increased expression and/or activity 
of ARG has a deep impact on NOS efficiency. As an example, arginase activity is increased 
in type 2 diabetic subjects with impaired NOS activity, and such impairment correlates with 
the degree of hyperglycemia and is reduced by insulin  [14] .
 Arginine Controls Arginase Expression and May Be Used as a Fuel 
 Exogenous arginine induces both ARG 1 and ARG 2 expression  [10, 15] . Thus, eventu-
ally, the more arginine is introduced, the more it is destroyed. Accordingly, it has been dem-
onstrated that in the liver, arginase activities strongly correlate with arginine concentrations, 
and inhibition of arginases peculiarly enhances the activity of the cytokine-inducible iso-
form of NOS (iNOS), which, in turn, activates cyclo-oxygenase-2 and inflammation  [12] .
 Increased arginase activity would also negatively influence eNOS efficiency in produc-
ing NO, as observed in hypertensive humans where exogenous arginine is ineffective in im-
proving vasodilation  [16] .
 Arginine metabolism by arginases may have other inhibitory effects on eNOS activity 
and NO production because urea produced by arginases is a potent inhibitor of ASL  [17] , one 
of the enzymes recycling citrulline to arginine, which colocalizes with eNOS. Also, ornithine 
produced from arginine when urea is cleaved by arginases ( fig. 1 ) is a potent inhibitor of ARG 
1, but a poor inhibitor of ARG 2  [18] .
 Additionally, arginine is a potent secretagogue for glucagon, which induces arginase in 
liver perivenous cells and the catabolism of arginine to ornithine  [19] , but also antagonizes 
insulin and causes insulin resistance  [20] . This is important because insulin resistance in-
creases the expression of glutaminase in liver periportal cells, thus promoting the wasting of 
glutamine, which is necessary for recycling ornithine to citrulline ( fig. 1 ). Dietary glutamate 
and glutamine are nearly totally oxidized by small-intestine epithelial cells during absorp-
tion and are actively taken up from the blood stream when synthesized elsewhere because 
they are the most important fuel for the intestinal tissues  [21, 22] . By using isotopically la-
beled molecules, it was found that the amino group of glutamine labels the three nitrogens 
of citrulline almost equally; only a nonspecific incorporation of carbon atoms from gluta-
mine oxidation into carbamoyl phosphate – necessary for citrulline synthesis – has been 
observed  [23] . Therefore, glutamine is synthesized from glutamate, which in turn derives 
from the citric acid cycle through the export of   -ketoglutarate, a most important precursor 
of oxaloacetate. 
 The availability of glutamate, as that of aspartic acid (aspartate) necessary for aspartate 
synthase to start the recycling of citrulline to arginine, depends on the entry of glucose-de-
rived pyruvate into the mitochondria. As described elsewhere  [24] , the occurrence of insulin 
resistance triggers a prevalence of fatty-acid   -oxidation in providing acetate for citrate syn-
thesis. The prevalence of   -oxidation in providing acetate is accompanied by an inhibition 
of pyruvate dehydrogenase, preventing the entry into mitochondria of acetate derived from 
pyruvate and the entire glucose oxidation. Also, variations of the balances of NAD/NADH 
and NADP/NADPH in the cytoplasm due to changes in   -oxidation increase the drive of 
pyruvate towards oxaloacetate and then to citrate and fatty-acid synthesis, explaining the 
paradox that steatosis is present in cells where energy production is controlled by   -oxida-
tion in conditions of chronic insulin resistance.
 Intermediates of the citric acid cycle are necessary for the synthesis of nonessential AA, 
such as glutamic acid, glutamine and arginine, and for this purpose such intermediates have 
to be exported from the mitochondria to the cytoplasm. When export is possible, the citric 
acid cycle is defined as anaplerotic, in contrast with a cataplerotic cycle, which occurs when 
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export of intermediates is insufficient to maintain an adequate synthesis of nonessential AA, 
which is the case when aspartate and glutamate are no longer produced sufficiently. There-
fore, export of intermediates of the cycle is indispensable for anabolic purposes, but also sub-
tracts intermediates that would be recycled to the oxaloacetate, indispensable for condensa-
tion with acetate and for maintaining the cycle fully working by forming new citrate. Insuf-
ficient oxaloacetate availability into the cycle is followed both by a reduction of energy 
production and, subsequently, by a reduction of the synthesis of nonessential AA from in-
termediates of the cycle. This process, however, also triggers the entry of AA into mitochon-
dria to refuel the cycle of oxaloacetate precursors, mostly at the level of succinate or   -keto-
glutarate. Such phenomena explain the pathophysiological mechanism underlying the sar-
copenia/cachexia syndrome occurring in all conditions of peripheral insulin resistance. 
 It should be kept in mind that the prevalence of   -oxidation is unfavorable for the pro-
duction of energy not only because for any acetate produced from fatty acids the amount of 
ATP produced is 25% less than for any acetate produced from glucose, but also because the 
citric acid cycle is ‘choked’ by the lack of oxaloacetate in amounts sufficient to maintain the 
efficiency of the citric acid cycle in both exporting intermediates (anaplerotic citric acid cy-
cle) or maintaining a full efficiency for citrate and ATP synthesis. 
 Proof of this concept is that trimetazidine, an inhibitor of   -oxidation, improves ven-
tricular ejection fraction in patients with insulin resistance in whom   -oxidation prevails 
 [25] . Glutamine and arginine are excellent substrates for the citric acid cycle because both 
may be efficient precursors of   -ketoglutarate, and this explains why, in demanding meta-
bolic conditions such as in sepsis, both these AA can be found substantially decreased in 
plasma  [26] . Moreover, elevated concentrations of glutamine increase ASsynth expression 
and activity in intestinal cells, similarly to interleukin (IL)-1  , but the simultaneous presence 
of glutamine and IL-1 suppresses ASsynth expression and activity  [27] . In contrast, gluta-
mine inhibits arginine synthesis in endothelial cells by directly decreasing ASsynth activity 
and also through a competitive inhibition of citrulline uptake  [28] .
 In summary, oral arginine supplementation not only increases arginine disposal through 
urea synthesis, but also promotes insulin resistance, a detrimental condition that reduces the 
availability of components necessary for both de novo and recycling synthesis. Therefore, 
indications for glutamine supplementation, out of the scope of this review, should be care-
fully revised  [29] .
 Interactions between iNOS and eNOS and Control of eNOS Expression 
 Because arginine is necessary for iNOS to produce NO for bactericidal purposes in mac-
rophages and is also used by T lymphocytes for their own function and proliferation, argi-
nine availability is strictly linked to the immune response.  At variance with rodents, human 
macrophages express little arginase or iNOS unless activated  [30] , but their production of 
NO is indispensable for the defense against bacteria, as shown by the poor outcome of pa-
tients with sepsis and low plasma arginine  [31] . Inducible (i)NOS is not expressed constitu-
tively by most cells, but is highly inducible by bacterial endotoxins and inflammatory cyto-
kines. Unlike eNOS, iNOS are primarily cytosolic. Activation of macrophages through toll-
like receptor signaling pathways is an important component of the immune defense, but 
some pathogens, such as mycobacteria, use this pathway to increase the expression of ARG 
1, reduce arginine availability and create conditions of resistance to infections  [32] . Changes 
in the immune response may either be due to excessive activation, as observed in asthma, or 
defective activation, as in sepsis. However, NO production by NOS generates N G -hydroxyl-
 L -arginine (NOHA), which is a potent natural inhibitor of arginase, reducing arginine avail-
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ability for urea synthesis. By this mechanism, elevated concentrations of NOHA improve 
arginine availability for NO synthesis. In turn, agmatine, generated from arginine ( fig. 1 ), is 
a weak inhibitor of NOS but decreases the expression of iNOS and can increase endothelial 
NO production by binding to a cell surface imidazoline receptor and increasing cytosolic 
calcium  [33] . Furthermore, the assembly of iNOS depends on arginine presence for dimer-
ization, and the incomplete dimerization when arginase activity is prevalent would mean 
incomplete iNOS coupling and the presence of inactive enzymes  [34] . The reader is referred 
to a comprehensive review on the synthesis and metabolism of endogenous arginine ana-
logues with inhibitory activity on NOS and arginases other than NOHA  [35] .
 To further complicate the picture, while the two arginase isoforms (I and II) are induced 



































 Fig. 1. A schematic representation of urea (arginine to ornithine-citrulline cycle), of citrulline-arginine 
recycling and of their relationship with the citric acid cycle (CAC). The CAC is the source of   -ketogluta-
rate (  KG) and aspartate, and those two molecules are the link between the CAC and the urea and citrul-
line-arginine cycles. Aspartate is necessary for starting the recycling of citrulline to arginine by ASsynth. 
Arginine induces arginase expression activity (flash sign) and activates N-acetylglutamate (NAG) syn-
thase, an allosteric activator indispensable for the synthesis of carbamoyl phosphate (CPS) and the action 
of ornithine transcarbamylase action. NAG synthesis depends on the availability of glutamine (GlutN), 
which is synthesized de novo from   KG exported from the CAC, via glutamate synthesis (GlutA). Urea 
produced by arginases is a potent inhibitor of ASL. Ornithine derived from arginase action is both the 
substrate and the product for the synthesis or metabolism of proline and glutamine, and glutamic semi-
aldehyde (GSA) is the intermediate of those reactions, mediated by ornithine aminotransferase (OAT), 
the enzyme exchanging one amino group between glutamate and   KG. Proline inhibits GSA synthesis by 
negative feedback on   2 -pyrrolidine-5-carboxylate synthase (P5Csynth). Ornithine inhibits P5Csynth 
and proline synthesis from GSA. Agmatine increases eNOS and decreases inducible NOS activity. Argi-
nine metabolism by NOS and protein catabolism produces variable amounts of physiological arginine 
competitors with inhibitory properties, here represented as NOHA and asymmetric dimethylarginine 
(ADMA). The bar signal at the end of dotted lines indicates inhibition. The flash sign inserted on dotted 
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expression of both NOS and of arginases may be induced by endotoxins and T-helper-1 cy-
tokines (IL-1, TNF-  , interferon-  ). It should also be remembered that ornithine is an im-
portant precursor both of polyamines needed for cell proliferation and of proline needed for 
collagen synthesis and wound healing. Therefore, T-helper-1 cells induce iNOS, while the 
induction of arginase by T-helper-2 cells suppresses iNOS production. This complex inter-
regulation is further controlled by arginine availability  [36] . There must be some kind of 
competition for arginine between iNOS and eNOS, since, in a model of allergic asthma, the 
overexpression of eNOS in lung endothelial cells results in both increased eNOS activity and 
NO production, and after sensitization with ovalbumin thoracic lymph node cells produced 
significantly less cytokines, with a 50% reduction in the number of lymphocytes and eosin-
ophils in the lung lavage fluid and an abolishment of airway methacholine hyperresponsive-
ness. The hyperresponsiveness of airways in asthma is associated with enhanced iNOS ex-
pression and activity of T cells, with increased levels of exhaled NO. The balance between 
the prevailing NO production by iNOS and the bronchodilator (by smooth muscle relax-
ation) NO production by eNOS may be a key to understanding asthma  [37] .
Our group has shown that aging increases iNOS and decreases eNOS expression in the 
kidneys. We also showed that supplementation with a cluster of essential AA, in specific stoi-
chiometric ratios tailored for mammalian (hence, human) needs (CATHON TM ;  table 1 ), is 
effective in reversing the balance among iNOS and eNOS, with improved expression of 
eNOS, increased mitochondrial biogenesis and cytochrome C oxidase activity, and parallel 
reduction of glomerular iNOS expression and fibrosis  [38] . Similar effects had previously 
been observed in skeletal and myocardial muscles  [39] . Even more interestingly, we have 
shown that the long-term supplementation with the same formulation increases mitochon-
drial biogenesis and upregulates gene systems for the defense against reactive oxygen species 
(ROS) and longevity. This was related to both increased expression of peroxisome prolifera-
tor-activated receptor-  coactivator-1  (PGC-1  ) and of sirtuin-1 (SIRT-1) expression and 
mammalian target of rapamycin (mTOR) signaling. Thus, we observed that eNOS expres-
sion and mitochondrial biogenesis are strictly linked  [40] . The CATHON formulation does 
not contain arginine and yet proved to be extremely efficient in promoting improved physi-
cal activity both in diabetic patients with chronic heart failure  [41] and patients with chron-












T his formulation has peculiarities in that it contains two nones-
sential AA. Tyrosine is provided because it is an essential AA for all 
tissues apart from the liver. Cystine is contained in a peculiar molar 
ratio to methionine to meet sulfur AA requirements, minimizing the 
synthesis of homocysteine, the intermediate between methionine 
and cysteine.
Table 1. C luster of AA tailored 
to human needs (CATHON; 
proportions are based on 100 
mg, L-forms)
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umented  [42] . Interestingly, a ‘side effect’ of CATHON administration is improved insulin 
sensitivity, as shown by long-term supplementation studies in the elderly  [43] and, more re-
cently, in extremely severe intensive care unit patients  [44] . CATHON enhances insulin ac-
tion thanks to enhanced mTOR activity  [45] , with important clinical implications  [22] .
 As discussed above, insulin resistance conditions are characterized by a citric acid cycle 
unable to export intermediates and consuming excessive amounts of AA for energy produc-
tion, as shown in chronic heart failure patients submitted to light exercise  [46] . In such con-
ditions, as in any condition of unbalanced protein-calorie introduction, far more elevated 
amounts of essential AA than those usually contained in alimentary proteins in standard 
diets have to be provided to maintain the integrity of metabolism  [47] . Moreover, an in-
creased supplementation of essential AA not only improves energy production even in the 
most demanding conditions  [48] , but also improves the synthesis of any non-essential AA, 
replenishing the citric acid cycle and restoring the anaplerotic export of those intermediates 
necessary for maintaining the ubiquitous synthesis of any AA, glutamate and arginine in-
cluded. In my opinion, this is the main reason why immune response is improved in inten-
sive care patients  [42] and long-term-care acquired infections are reduced in elderly patients 
receiving CATHON supplementation  [49] .
 Concluding Remarks 
 Arginine metabolism is very complex, and equally complex and highly interregulated is 
the availability of arginine for the various metabolic pathways in which this AA is involved. 
Exogenous arginine supplementation should be avoided, because it does not resolve the rea-
sons underlying its excess consumption or blunted synthesis, and, on the contrary, may ac-
tually worsen them. The usual paradigm of clinical nutrition, assuming that what is lacking 
should be provided, may here prove to be wrong. A better alternative is the provision of suf-
ficient amounts of balanced formulations of essential AA, because these would better main-
tain and restore concentrations and metabolic pathways for the synthesis of this non-essen-
tial AA, and of its precursors and derivatives. Balanced formulations of essential AA are also 
the key to promoting gene expression of elements such as mTOR, PGC-1  , SIRT-1, and 
eNOS, consistent with the best possible metabolic performances in any physiological or path-
ological condition and at any age.
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